Newark, NJ, February 04, 2012 --(PR.com
)-- Plandai Biotechnology, Inc is a biotechnology company. The Company specializes in bioavailable extracts from live plant material. These extracts are key ingredients in end-use products found in key markets, such as food and beverage, cosmeceutical, nutraceutical and pharmaceutical.
Headquartered in Seattle, USA with offices in London, UK and Nelspruit, South Africa, the company’s vision is to transform the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability.
With more than 8500 acres of land and farms, and proprietary extraction technology, Plandai Biotechnology controls every aspect of the process, from growing the raw material on its farms in South Africa to producing the extracts, in house. This enables Plandai to guarantee continuity of supply as well as quality throughout the whole process.
Plandai currently extracts gallate catechins from green tea, catechin gallate (CG), epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene) from tomatoes, as well as citrus bioflavonoids and limoniods.
The company’s gallate catechin extract will be the active ingredient in formulated products supporting weight loss, anti-aging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
Plandai intends to sell its extracts to leading product manufacturers in many sectors including; Food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging and pharmaceutical.
About Wall Street Equities Research
Wall Street Equities Research is a professional equities research firm focused on US listed companies. Our research reports assist investors with their investment decisions based in depth analysis of US listed companies. For more information, visit our website at www.wallstreetequitiesresearch.com.